fashion -WSS

fashion

author：entertainment 2025-10-06 07:55:02 - browse：79687

FogPharma CEO Mathai Mammen Venrock

SAN FRANCISCO — Six months into his tenure as CEO of cancer startup FogPharma, Mathai Mammen is taking the stage at the Westin St. Francis Tuesday for what he’s calling a “big unveil” of how he’s reshaping the biotech. And he’s prepared to go against the grain.

Perhaps the most important thing he’s telling investors at the J.P. Morgan Healthcare Conference is that he plans to eventually pursue a rare Series E round, rather than an IPO or seeking out acquisition offers.

FogPharma last raised money in November 2022, and will need more cash to bring its lead drug past its ongoing Phase 1/2 trial. Most other biotechs in this position are anxiously eyeing the capital markets, hoping that conditions improve and make an IPO more feasible. But Mammen doesn’t see the point, at this stage. “There’s no reason to be a public company. I don’t know why you’d want to be, really,” he told STAT ahead of FogPharma’s presentation.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Health care court cases: Humana, Sutter, Novant

knowledge

WSS

The system is set up to fail children with medical complexity

New chart reveals military’s vast involvement in Operation Warp Speed

Grand jury probing Trump's efforts to overturn 2020 election did not meet Friday: Sources

5 takeaways from STAT's examination of Zynex Medical

Prosecutors say FTX founder Sam Bankman

What is artificial intelligence? Experts weigh in

focus

fashion

focus

Dobbs anniversary: the lost opportunity of abortion as health care

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

Psychedelics group wrestles with new pharma identity

What is artificial intelligence? Experts weigh in

Dobbs anniversary: the lost opportunity of abortion as health care

My daughter's legacy lives on through her writing, phage therapy

BioMarin wins approval for gene therapy to treat hemophilia A

'Essentially witchcraft:' A former naturopath takes on the field

FDA approval of Sarepta Duchenne genetic therapy gives me hope

ALS patient reclaims some autonomy thanks to wearable 'robot'

focus

Mega Millions jackpot grows to $720 million ahead of Friday's drawing

New chief aims to remake Sanofi Genzyme

Why the advice to take all your antibiotics may be wrong

Report captures long Covid’s disabling effects and policy challenges

Prosecutors say FTX founder Sam Bankman

Readers discuss the intersection of pregnancy and addiction

hotspot

knowledge

focus

explore